Malik Fady Ibraham sold $265K of CYTK
Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares of CYTOKINETICS INC (CYTK) at $75.82 ($0.27M total) on 2026-08-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and date by the EVP of R&D, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may briefly factor insider selling into sentiment, but 10b5-1 typically limits the signal strength.
What to watch
The article provides no context on total insider holdings changes beyond the post-transaction figure, and does not indicate whether other insiders filed concurrent transactions.
Background
This is an SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK).
Ticker impact
CYTOK insider Form 4 shows EVP R&D Malik Fady Ibraham sold 3,500 shares at $75.82 on 2026-08-18 under a 10b5-1 plan.
Low near-term impact; any reaction is likely muted and short-lived unless paired with other new CYTK-specific catalysts.
The filing is a disclosed open-market sale with an explicit pre-arranged 10b5-1 plan, reducing interpretive weight as a fresh bearish signal.
Market effects
No clear sector read-through from a single disclosed 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider sales can coincide with periods of reduced confidence or liquidity needs, so traders may still watch for follow-on selling patterns.
Key entities
- issuerCYTOKINETICS INC
Company whose insider transaction is disclosed on Form 4.
- insiderMalik Fady Ibraham
EVP Research and Development who sold 3,500 shares on 2026-08-18 under a 10b5-1 plan.
